BVS today
$10.86-$0.13 (-1.18%)close Nov 12, 2026Trend
DailyDowntrend (starting)
4 hourStrong Bearish
1 hourSymmetric Triangle
15 minLeaning Bullish
5 minStrong Bearish
Daily trend turns up above $15.89
Key levels
Resistance$11.93
Resistance$11.00
Support$10.09
Support$8.45
Latest news & SEC filings
AnalystCanaccord Genuity keeps Buy rating on Bioventus, cuts price target to $18
AnalystCanaccord Genuity keeps Buy rating on Bioventus, cuts target to $18
EarningsAdeia reports weaker Q3 earnings, shares fall in Tuesday pre-market
All BVS news →About Bioventus
Bioventus is a medical device maker focused on pain relief and musculoskeletal care. It sells knee osteoarthritis injections, nerve stimulation devices, ultrasonic bone-cutting tools, bone graft substitutes, and ultrasound therapy for slow-healing fractures. Its customers include physicians, hospitals, and surgery centers, reached through its own representatives as well as third-party distributors in the United States and other countries.
Based on the company's 10-K filed Mar 5, 2026.
Nasdaq · Healthcare
Bioventus Inc. (BVS)
What Is the Price Target for BVS?
SEPT Low Target
$15.00
SEPT Mid Target
$16.50
SEPT High Target
$18.00
Analyst Consensus
$16.50
Is BVS a Buy or Sell Right Now?
Thesis
- •Revenue growing -0.9% YoY with SLOWING trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for BVS.
Start Free Trial →Is BVS Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/E Forward, P/B, PEG, Analyst Consensus
Fair Value
$15.78
52
Moat Score
NARROW
8/9
Piotroski Score
1.8
Altman Z-Score
What Is Smart Money Doing with BVS?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| McMurry-Heath Michelle | director | Buy | 32,282 | - | Jun 2, 2026 |
| Ladone Mary Kay | director | Buy | 32,282 | - | Jun 2, 2026 |
| Cowdy Philip G. | director | Buy | 32,282 | - | Jun 2, 2026 |
| Beyer Pat | director | Buy | 32,282 | - | Jun 2, 2026 |
| Bartholdson John A. | director 10% owner | Buy | 32,282 | - | Jun 2, 2026 |
| NEELS GUIDO J | director | Buy | 32,282 | - | Jun 2, 2026 |
| STALNECKER SUSAN M | director | Buy | 32,282 | - | Jun 2, 2026 |
| NOHRA GUY P | director | Buy | 32,282 | - | Jun 2, 2026 |
| HAWKINS WILLIAM A | director | Buy | 39,789 | - | Jun 2, 2026 |
| SUTTER MARTIN P | director 10% owner | Buy | 32,282 | - | Jun 2, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →BVS Growth Story
Revenue YoY
-0.9%
3yr Revenue CAGR
3.5%
EPS Growth YoY
158.93%
FCF Growth YoY
90.8%
Revenue Trend
SLOWING
Dark Pool Trades for BVS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for BVS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:33 | $10.86 | 3,346 | $$36K | BUY |
| 21:00:31 | $10.86 | 2,180 | $$24K | BUY |
| 21:00:02 | $10.86 | 1,200 | $$13K | BUY |
| 20:59:21 | $10.88 | 1,100 | $$12K | BUY |
| 20:59:07 | $10.87 | 1,200 | $$13K | SELL |
5 dark pool trades shown · $$98K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Bioventus Inc. (BVS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →BVS — frequently asked questions
What is BVS stock price today?
Bioventus Inc. (BVS) is at $10.86, down 1.18% (-$0.13) at the Nov 12, 2026 close.
Why is BVS stock moving today?
Latest BVS news — Nov 4, 2026: Canaccord Genuity keeps Buy rating on Bioventus, cuts price target to $18 · Nov 3, 2026: Canaccord Genuity keeps Buy rating on Bioventus, cuts target to $18
What is the BVS price target?
The average analyst price target for BVS is $16.50, ranging from $15 to $18, based on 2 analysts. Latest: Canaccord Genuity maintains on Nov 3, 2026.
What do analysts rate BVS?
Analyst ratings for BVS: 0 Buy, 3 Hold, 0 Sell — consensus Hold.
Did BVS beat earnings?
BVS last reported on Nov 2, 2026: EPS $0.17 vs $0.15 expected — a beat of 13.6%.
What is BVS's P/E ratio?
BVS trades at a P/E of 13.7 vs a Healthcare average of 17.7.
Does BVS pay a dividend?
BVS does not currently pay a dividend.
What are BVS support and resistance levels?
Support: $10.09, $8.45, $7.59. Resistance: $11.00, $11.93, $13.15.
What are insiders doing with BVS?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on BVS?
Nov 4, 2026: Canaccord Genuity keeps Buy rating on Bioventus, cuts price target to $18 · Nov 3, 2026: Canaccord Genuity keeps Buy rating on Bioventus, cuts target to $18 · Nov 3, 2026: Adeia reports weaker Q3 earnings, shares fall in Tuesday pre-market